Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report
Аутори
Malfertheiner, PeterMegraud, Francis
Rokkas, Theodore
Gisbert, Javier P.
Liou, Jyh-Ming
Schulz, Christian
Gasbarrini, Antonio
Hunt, Richard H.
Leja, Marcis
O’Morain, Colm
Rugge, Massimo
Suerbaum, Sebastian
Tilg, Herbert
Sugano, Kentaro
El-Omar, Emad M.
Agreus, L.
Bazzoli, F
Bordin, D
Loginov, A.S.
Mario, F. D.
Dinis-Ribeiro, M.
Engstrand, Lars
Fallone, C
Goh, K.L.
Graham, David
Kuipers, E.J.
Kupcinskas, J.
Lanas, A.
Machado, Jose C.
Mahachai, V.
Marshall, B.J.
Milosavljevic, Tomica
Moss, S.F.
Park, J.Y.
Niv, Y.
Rajilić-Stojanović, Mirjana
Ristimaki, A
Smith, S.
Tepeš, Bojan
Wu, C.Y.
Zhou, L.
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
elicobacter pylori Infection is formally recognised as an infectious disease, an entity that is now included in the International Classification of Diseases 11th Revision. This in principle leads to the recommendation that all infected patients should receive treatment. In the context of the wide clinical spectrum associated with Helicobacter pylori gastritis, specific issues persist and require regular updates for optimised management. The identification of distinct clinical scenarios, proper testing and adoption of effective strategies for prevention of gastric cancer and other complications are addressed. H. pylori treatment is challenged by the continuously rising antibiotic resistance and demands for susceptibility testing with consideration of novel molecular technologies and careful selection of first line and rescue therapies. The role of H. pylori and antibiotic therapies and their impact on the gut microbiota are also considered. Progress made in the management of H. pylori i...nfection is covered in the present sixth edition of the Maastricht/ Florence 2021 Consensus Report, key aspects related to the clinical role of H. pylori infection were re-evaluated and updated. Forty-one experts from 29 countries representing a global community, examined the new data related to H. pylori infection in five working groups: (1) indications/associations, (2) diagnosis, (3) treatment, (4) prevention/gastric cancer and (5) H. pylori and the gut microbiota. The results of the individual working groups were presented for a final consensus voting that included all participants. Recommendations are provided on the basis of the best available evidence and relevance to the management of H. pylori infection in various clinical fields.
Извор:
Guidelines, 2022, 71, 9, 1724-1762Институција/група
Tehnološko-metalurški fakultetTY - JOUR AU - Malfertheiner, Peter AU - Megraud, Francis AU - Rokkas, Theodore AU - Gisbert, Javier P. AU - Liou, Jyh-Ming AU - Schulz, Christian AU - Gasbarrini, Antonio AU - Hunt, Richard H. AU - Leja, Marcis AU - O’Morain, Colm AU - Rugge, Massimo AU - Suerbaum, Sebastian AU - Tilg, Herbert AU - Sugano, Kentaro AU - El-Omar, Emad M. AU - Agreus, L. AU - Bazzoli, F AU - Bordin, D AU - Loginov, A.S. AU - Mario, F. D. AU - Dinis-Ribeiro, M. AU - Engstrand, Lars AU - Fallone, C AU - Goh, K.L. AU - Graham, David AU - Kuipers, E.J. AU - Kupcinskas, J. AU - Lanas, A. AU - Machado, Jose C. AU - Mahachai, V. AU - Marshall, B.J. AU - Milosavljevic, Tomica AU - Moss, S.F. AU - Park, J.Y. AU - Niv, Y. AU - Rajilić-Stojanović, Mirjana AU - Ristimaki, A AU - Smith, S. AU - Tepeš, Bojan AU - Wu, C.Y. AU - Zhou, L. PY - 2022 UR - http://TechnoRep.tmf.bg.ac.rs/handle/123456789/6050 AB - elicobacter pylori Infection is formally recognised as an infectious disease, an entity that is now included in the International Classification of Diseases 11th Revision. This in principle leads to the recommendation that all infected patients should receive treatment. In the context of the wide clinical spectrum associated with Helicobacter pylori gastritis, specific issues persist and require regular updates for optimised management. The identification of distinct clinical scenarios, proper testing and adoption of effective strategies for prevention of gastric cancer and other complications are addressed. H. pylori treatment is challenged by the continuously rising antibiotic resistance and demands for susceptibility testing with consideration of novel molecular technologies and careful selection of first line and rescue therapies. The role of H. pylori and antibiotic therapies and their impact on the gut microbiota are also considered. Progress made in the management of H. pylori infection is covered in the present sixth edition of the Maastricht/ Florence 2021 Consensus Report, key aspects related to the clinical role of H. pylori infection were re-evaluated and updated. Forty-one experts from 29 countries representing a global community, examined the new data related to H. pylori infection in five working groups: (1) indications/associations, (2) diagnosis, (3) treatment, (4) prevention/gastric cancer and (5) H. pylori and the gut microbiota. The results of the individual working groups were presented for a final consensus voting that included all participants. Recommendations are provided on the basis of the best available evidence and relevance to the management of H. pylori infection in various clinical fields. T2 - Guidelines T1 - Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report EP - 1762 IS - 9 SP - 1724 VL - 71 DO - 10.1136/gutjnl-2022-327745 ER -
@article{ author = "Malfertheiner, Peter and Megraud, Francis and Rokkas, Theodore and Gisbert, Javier P. and Liou, Jyh-Ming and Schulz, Christian and Gasbarrini, Antonio and Hunt, Richard H. and Leja, Marcis and O’Morain, Colm and Rugge, Massimo and Suerbaum, Sebastian and Tilg, Herbert and Sugano, Kentaro and El-Omar, Emad M. and Agreus, L. and Bazzoli, F and Bordin, D and Loginov, A.S. and Mario, F. D. and Dinis-Ribeiro, M. and Engstrand, Lars and Fallone, C and Goh, K.L. and Graham, David and Kuipers, E.J. and Kupcinskas, J. and Lanas, A. and Machado, Jose C. and Mahachai, V. and Marshall, B.J. and Milosavljevic, Tomica and Moss, S.F. and Park, J.Y. and Niv, Y. and Rajilić-Stojanović, Mirjana and Ristimaki, A and Smith, S. and Tepeš, Bojan and Wu, C.Y. and Zhou, L.", year = "2022", abstract = "elicobacter pylori Infection is formally recognised as an infectious disease, an entity that is now included in the International Classification of Diseases 11th Revision. This in principle leads to the recommendation that all infected patients should receive treatment. In the context of the wide clinical spectrum associated with Helicobacter pylori gastritis, specific issues persist and require regular updates for optimised management. The identification of distinct clinical scenarios, proper testing and adoption of effective strategies for prevention of gastric cancer and other complications are addressed. H. pylori treatment is challenged by the continuously rising antibiotic resistance and demands for susceptibility testing with consideration of novel molecular technologies and careful selection of first line and rescue therapies. The role of H. pylori and antibiotic therapies and their impact on the gut microbiota are also considered. Progress made in the management of H. pylori infection is covered in the present sixth edition of the Maastricht/ Florence 2021 Consensus Report, key aspects related to the clinical role of H. pylori infection were re-evaluated and updated. Forty-one experts from 29 countries representing a global community, examined the new data related to H. pylori infection in five working groups: (1) indications/associations, (2) diagnosis, (3) treatment, (4) prevention/gastric cancer and (5) H. pylori and the gut microbiota. The results of the individual working groups were presented for a final consensus voting that included all participants. Recommendations are provided on the basis of the best available evidence and relevance to the management of H. pylori infection in various clinical fields.", journal = "Guidelines", title = "Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report", pages = "1762-1724", number = "9", volume = "71", doi = "10.1136/gutjnl-2022-327745" }
Malfertheiner, P., Megraud, F., Rokkas, T., Gisbert, J. P., Liou, J., Schulz, C., Gasbarrini, A., Hunt, R. H., Leja, M., O’Morain, C., Rugge, M., Suerbaum, S., Tilg, H., Sugano, K., El-Omar, E. M., Agreus, L., Bazzoli, F., Bordin, D., Loginov, A.S., Mario, F. D., Dinis-Ribeiro, M., Engstrand, L., Fallone, C., Goh, K.L., Graham, D., Kuipers, E.J., Kupcinskas, J., Lanas, A., Machado, J. C., Mahachai, V., Marshall, B.J., Milosavljevic, T., Moss, S.F., Park, J.Y., Niv, Y., Rajilić-Stojanović, M., Ristimaki, A., Smith, S., Tepeš, B., Wu, C.Y.,& Zhou, L.. (2022). Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. in Guidelines, 71(9), 1724-1762. https://doi.org/10.1136/gutjnl-2022-327745
Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou J, Schulz C, Gasbarrini A, Hunt RH, Leja M, O’Morain C, Rugge M, Suerbaum S, Tilg H, Sugano K, El-Omar EM, Agreus L, Bazzoli F, Bordin D, Loginov A, Mario FD, Dinis-Ribeiro M, Engstrand L, Fallone C, Goh K, Graham D, Kuipers E, Kupcinskas J, Lanas A, Machado JC, Mahachai V, Marshall B, Milosavljevic T, Moss S, Park J, Niv Y, Rajilić-Stojanović M, Ristimaki A, Smith S, Tepeš B, Wu C, Zhou L. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. in Guidelines. 2022;71(9):1724-1762. doi:10.1136/gutjnl-2022-327745 .
Malfertheiner, Peter, Megraud, Francis, Rokkas, Theodore, Gisbert, Javier P., Liou, Jyh-Ming, Schulz, Christian, Gasbarrini, Antonio, Hunt, Richard H., Leja, Marcis, O’Morain, Colm, Rugge, Massimo, Suerbaum, Sebastian, Tilg, Herbert, Sugano, Kentaro, El-Omar, Emad M., Agreus, L., Bazzoli, F, Bordin, D, Loginov, A.S., Mario, F. D., Dinis-Ribeiro, M., Engstrand, Lars, Fallone, C, Goh, K.L., Graham, David, Kuipers, E.J., Kupcinskas, J., Lanas, A., Machado, Jose C., Mahachai, V., Marshall, B.J., Milosavljevic, Tomica, Moss, S.F., Park, J.Y., Niv, Y., Rajilić-Stojanović, Mirjana, Ristimaki, A, Smith, S., Tepeš, Bojan, Wu, C.Y., Zhou, L., "Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report" in Guidelines, 71, no. 9 (2022):1724-1762, https://doi.org/10.1136/gutjnl-2022-327745 . .